Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Total Non-Current Liabilities: 2015-2025

Historic Total Non-Current Liabilities for Spyre Therapeutics (SYRE) over the last 8 years, with Sep 2025 value amounting to $46.3 million.

  • Spyre Therapeutics' Total Non-Current Liabilities fell 19.58% to $46.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.3 million, marking a year-over-year decrease of 19.58%. This contributed to the annual value of $54.1 million for FY2024, which is 69.05% up from last year.
  • As of Q3 2025, Spyre Therapeutics' Total Non-Current Liabilities stood at $46.3 million, which was down 34.53% from $70.7 million recorded in Q1 2025.
  • In the past 5 years, Spyre Therapeutics' Total Non-Current Liabilities registered a high of $70.7 million during Q1 2025, and its lowest value of $21.5 million during Q1 2022.
  • In the last 3 years, Spyre Therapeutics' Total Non-Current Liabilities had a median value of $46.3 million in 2025 and averaged $47.8 million.
  • In the last 5 years, Spyre Therapeutics' Total Non-Current Liabilities skyrocketed by 80.63% in 2021 and then plummeted by 62.77% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $26.0 million in 2021, then tumbled by 45.77% to $21.5 million in 2022, then reached $32.0 million in 2023, then skyrocketed by 69.05% to $54.1 million in 2024, then fell by 19.58% to $46.3 million in 2025.
  • Its Total Non-Current Liabilities stands at $46.3 million for Q3 2025, versus $70.7 million for Q1 2025 and $54.1 million for Q4 2024.